Carcinoma, Non-small-cell Lung — Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Citation(s)
Multicenter Phase II Study Evaluating Docetaxel, CDDP, and Cetuximab as Induction Regimen Prior to Surgery in Chemo-naive Patients With NSCLC Stage IB, II and IIIA